阿布昔替尼治疗6例激素诱导的玫瑰痤疮样皮炎疗效观察  

Observation on Efficacy of Abrocitinib for 6 Cases of Steroid-Induced Rosacea-Like Dermatitis

作　　者：孟潇琦 刘亭微 许阳[1] MENG Xiaoqi;LIU Tingwei;XU Yang(Department of Dermatology,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院皮肤科,江苏南京210029

出　　处：《皮肤科学通报》2024年第6期660-665,共6页Dermatology Bulletin

摘　　要：目的探讨高选择性JAK1抑制剂治疗激素诱导的玫瑰痤疮样皮炎(steroid-induced rosacea-like dermatitis,SIRD)的临床效果及安全性。方法纳入本院门诊SIRD患者6例,使用口服JAK1抑制剂阿布昔替尼治疗,起始剂量100 mg/d,每两周随访观察疗效及安全性,治疗显效者用药时间间隔逐步顺延12 h直至停药,疗效不佳者双倍剂量口服。结果阿布昔替尼显著改善了6例患者的临床症状,其中3例已顺利停药且病情无反复,1例患者用药2周出现纳差、恶心的消化道症状,予停药8周后再次启用阿布昔替尼治疗,未见明显不良反应。结论JAK1抑制剂是一种治疗SIRD的潜在药物选择,JAK1通路可能在SIRD发病机制中起重要作用。Objective To explore the clinical efficacy and safety of highly selective JAK1 inhibitors in the treatment of steroid-induced rosacea-like dermatitis(SIRD).Methods Six patients with SIRD from the outpatient department of our hospital were included.They were treated with oral JAK1 inhibitor abrocitinib,with an initial dose of 100 mg/day.Follow-up visits were conducted every two weeks to observe the efficacy and safety.For those with significant therapeutic effects,the time interval between doses was gradually extended by 12 hours until drug withdrawal.For those with poor therapeutic responses,the dose was doubled.Results Abrocitinib significantly improved the clinical symptoms of all 6 patients.Among them,3 patients have successfully stopped the medication without recurrence.One patient experienced gastrointestinal symptoms such as anorexia and nausea two weeks after administration.After drug withdrawal for eight weeks,abrocitinib was re-administered,and no obvious adverse reactions were observed.Conclusion JAK1 inhibitors represent a potential drug choice for the treatment of SIRD,and the JAK1 pathway may play a crucial role in the pathogenesis of SIRD.

关 键 词：JAK-STAT JAK1抑制剂 阿布昔替尼 激素诱导的玫瑰痤疮样皮炎 

分 类 号：R758[医药卫生—皮肤病学与性病学]